6JH0 Stock Chart & Stats
€0.80
-€0.07(-6.74%)
At close: 4:00 PM EDT
€0.80
-€0.07(-6.74%)
Day’s Range― - ―
52-Week Range€0.81 - €2.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.74M
Enterprise Value€11.67M
Total Cash (Recent Filing)€17.96M
Total Debt (Recent Filing)€2.18M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 05, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding9,858,383
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.89Price Target Upside511.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Cell-Therapy PipelineIN8bio is focused on γδ T-cell immunotherapies for difficult-to-treat cancers, including glioblastoma and leukemia. Concentration on specialized cell therapy and serious unmet medical needs could support meaningful clinical differentiation if its candidates demonstrate durable safety and efficacy.
Low LeverageModest leverage gives IN8bio less debt-related pressure than a heavily financed development company and preserves flexibility while programs advance. Low debt can reduce fixed obligations and refinancing exposure, although it does not eliminate the need for future equity or other external funding.
Improving Loss And Cash-Burn TrendThe reduction in net losses and free-cash-flow burn versus 2023–2024 indicates better spending discipline and a more favorable operating trajectory. Continued improvement could extend financial runway and make capital deployment more efficient as the clinical pipeline progresses.
Bears Say
No Commercial RevenueIN8bio has no product revenue to fund research, clinical development, or corporate operations, leaving its financial outlook dependent on advancing candidates rather than established commercial demand. Until a program reaches commercialization, revenue visibility and internally generated funding remain absent.
Persistent Losses And Cash BurnOngoing negative operating and free cash flow shows that the business currently consumes capital to sustain development activities. Persistent burn can constrain the pace of trials, increase dependence on financing markets, and make future progress sensitive to available funding and capital allocation.
Declining Equity And AssetsThe decline in equity and total assets reflects cumulative losses and capital erosion during the development stage. A shrinking balance-sheet base reduces financial resilience and may require additional external capital, potentially affecting existing holders and the company’s ability to sustain long-term programs.
IN8bio News
6JH0 FAQ
What was IN8bio’s price range in the past 12 months?
IN8bio lowest stock price was €0.81 and its highest was €2.12 in the past 12 months.
What is IN8bio’s market cap?
IN8bio’s market cap is €9.74M.
When is IN8bio’s upcoming earnings report date?
IN8bio’s upcoming earnings report date is Nov 05, 2026 which is in 18 days.
How were IN8bio’s earnings last quarter?
IN8bio released its earnings results on Aug 06, 2026. The company reported -€0.222 earnings per share for the quarter, beating the consensus estimate of -€0.306 by €0.084.
Is IN8bio overvalued?
According to Wall Street analysts IN8bio’s price is currently Undervalued.
Does IN8bio pay dividends?
IN8bio does not currently pay dividends.
What is IN8bio’s EPS estimate?
IN8bio’s EPS estimate is -0.3.
How many shares outstanding does IN8bio have?
IN8bio has 9,858,383 shares outstanding.
What happened to IN8bio’s price movement after its last earnings report?
IN8bio reported an EPS of -€0.222 in its last earnings report, beating expectations of -€0.306. Following the earnings report the stock price went up 1.235%.
Which hedge fund is a major shareholder of IN8bio?
Currently, no hedge funds are holding shares in DE:6JH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IN8bio
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
6JH0 Stock 12 Month Forecast
Average Price Target
€4.89
▲(511.81% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
―
Aprea Therapeutics
―